Saul Priceman

14PUBLICATIONS
62CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyMolecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 12, 2026
Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment.

|May 12, 2026
Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

|Apr 03, 2026
A class act: HDAC1- <i>Malat1</i> regulates MDSC apoptosis and cell cycling to decrease suppression of T cells.

Aaron G Baugh, Yingtong Liu, Edgar Gonzalez

|Oct 22, 2025
Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models.

Koichi Sasaki, Vipul Bhatia, Yuta Asano

|Oct 01, 2025
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery.

John P Murad, Lea Christian, Reginaldo Rosa

|Aug 11, 2025
Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors.

Anthony K Park, Isabel Monroy, Yuwei Ren

Pageof 3

Frequent Collaborators

4 joint publications

Stephen J Forman

4 joint publications

John K Lee

4 joint publications

Jun Ishihara

3 joint publications

Anthony K Park